NeuroSense Therapeutics has successfully completed the in-life phase of its nine-month non-rodent toxicity study for drug candidate PrimeC. The study, which was initiated in November 2023 following discussions with the U.S. Food and Drug Administration (FDA) regarding trial design, has yielded positive results.The successful completion of this toxicity study aligns with the company's regulatory strategy and provides further validation of PrimeC's long-term safety profile, marking a significant milestone in the drug's development pathway.

NeuroSense Therapeutics has successfully completed the in-life phase of its nine-month non-rodent toxicity study for drug candidate PrimeC. The study, which was initiated in November 2023 following discussions with the U.S. Food and Drug Administration (FDA) regarding trial design, has yielded positive results.The successful completion of this toxicity study aligns with the company's regulatory strategy and provides further validation of PrimeC's long-term safety profile, marking a significant milestone in the drug's development pathway.